Targeted therapies: how personal should we go?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacogenomics

Background:

• Targeted cancer therapies aim to inhibit oncogenic proteins crucial for tumor growth.
• The traditional approach correlates a single gene mutation with drug response, but this is often insufficient.
• Emerging evidence suggests nuanced responses based on specific mutations within a gene.

Purpose of the Study:

• To analyze the genetic, biological, and biochemical differences of individual mutations within cancer genes.
• To critically evaluate the role of specific mutations in predicting sensitivity and resistance to targeted therapies.
• To discuss implications for personalized cancer treatment strategies.

Main Methods:

• Literature review and critical analysis of existing data.
• Examination of genetic alterations in key cancer genes (e.g., EGFR, PIK3CA, KRAS).
• Assessment of signaling pathway complexity in determining therapeutic outcomes.

Main Results:

• Different mutations within the same cancer gene can lead to distinct sensitivities to targeted drugs.
• The overall genetic context, including upstream and parallel pathways, is a critical determinant of treatment response.
• A simplistic binary mutation-drug correlation is inadequate for predicting therapeutic success.

Conclusions:

• Personalized cancer therapy requires a comprehensive understanding of individual tumor genetics beyond single mutations.
• The genetic milieu significantly impacts patient response to targeted agents.
• Future strategies must account for pathway complexity to optimize treatment selection.